SynthesisThe European journal of health economics : HEPAC : health economics in prevention and care2019
How relevant are social costs in economic evaluations? The case of Alzheimer's disease.
Synthesis in The European journal of health economics : HEPAC : health economics in prevention and care, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Does the inclusion of societal costs change the economic evaluations recommendations? A systematic review for multiple sclerosis disease.The European journal of health economics : HEPAC : health economics in prevention and care · 2023Pooled it
- EQ-5D-5L or EQ-HWB-S: Which is the Better Instrument for Capturing Spillover Effects in Parental Carers of Children with COVID-19?PharmacoEconomics · 2025Article
- Time value of informal care of people with alzheimer's disease in Spain: a population-based analysis.The European journal of health economics : HEPAC : health economics in prevention and care · 2025Article
- Comparison of Caregiver and General Population Preferences for Dependency-Related Health States.Applied health economics and health policy · 2025Article
- On spillovers in economic evaluations: definition, mapping review and research agenda.The European journal of health economics : HEPAC : health economics in prevention and care · 2024Review
- Projected costs of informal care for older people in England.The European journal of health economics : HEPAC : health economics in prevention and care · 2024Article
- A 14-Year Longitudinal Analysis of Healthcare Expenditure on Dementia and Related Factors (DEMENCOST Study).Journal of Alzheimer's disease : JAD · 2023Article
- The Humanistic and Economic Burden of Alzheimer's Disease.Neurology and therapy · 2022Review
- Cost-effectiveness of pharmacological therapies for people with Alzheimer's disease and other dementias: a systematic review and meta-analysis.Cost effectiveness and resource allocation : C/E · 2022Review
- The economic burden of knee and hip osteoarthritis: absenteeism and costs in the Dutch workforce.BMC musculoskeletal disorders · 2022Article
- Article
- Assessing the Effect of Including Social Costs in Economic Evaluations of Diabetes-Related Interventions: A Systematic Review.ClinicoEconomics and outcomes research : CEOR · 2021Review
- The Burden of Spinal Muscular Atrophy on Informal Caregivers.International journal of environmental research and public health · 2020Article
- Considering the societal perspective in economic evaluations: a systematic review in the case of depression.Health economics review · 2020Review
- Shadow and extended shadow cost sharing associated to informal long-term care: the case of Spain.Health economics review · 2020Article
- Economic valuation of informal care provided to people after a myocardial infarction in France.BMC health services research · 2019Article
Corrections and comments
- Erratum issued
Authors and funding
5 authors.
Funding
Abstract
backgroundThe main objective of this study was to analyse how the inclusion (exclusion) of social costs can alter the results and conclusions of economic evaluations in the field of Alzheimer's disease interventions.
methodsWe designed a systematic review that included economic evaluations in Alzheimer's disease. The search strategy was launched in 2000 and ran until November 2018. The inclusion criteria were: being an original study published in a scientific journal, being an economic evaluation of any intervention related to Alzheimer's disease, including social costs (informal care costs and/or productivity losses), being written in English, using QALYs as an outcome for the incremental cost-utility analysis, and separating the results according to the perspective applied.
resultsIt was finally included 27 studies and 55 economic evaluations. Around 11% of economic evaluations changed their main conclusions. More precisely, three of them concluded that the new intervention became cost-effective when the societal perspective was considered, whereas when using just the health care payer perspective, the new intervention did not result in a cost-utility ratio below the threshold considered. Nevertheless, the inclusion of social cost can also influence the results, as 37% of the economic evaluations included became the dominant strategy after including social costs when they were already cost-effective in the health care perspective.
conclusionsSocial costs can substantially modify the results of the economic evaluations. Therefore, taking into account social costs in diseases such as Alzheimer's can be a key element in making decisions about public financing and pricing of health interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.